Molecular Characterization of Mammalian bHLH-PAS Transcription Factors
哺乳动物 bHLH-PAS 转录因子的分子表征
基本信息
- 批准号:9113818
- 负责人:
- 金额:$ 38.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:ARNT geneAgonistArchitectureAryl Hydrocarbon ReceptorBindingBiochemicalBiological AssayBiologyBiopsyCell physiologyCellsCellular biologyChemicalsComplementComplexDNADNA BindingDNA Binding DomainDimerizationDiseaseDrug Metabolic DetoxicationFamilyFamily memberGene ExpressionGenesGeneticGenetic ProgrammingGenetic TranscriptionGoalsHelix-Turn-Helix MotifsHeterodimerizationHumanHypoxia Inducible FactorImmunityInvestigationKnowledgeLigand BindingLigandsLinkLocationMalignant NeoplasmsMammalsMapsMediatingMetabolicMolecularMutationNeoplasm MetastasisNeuronsPathway interactionsPositioning AttributePropertyProteinsReportingResponse ElementsSchizophreniaSeriesSignal TransductionStructureStructure-Activity RelationshipSubgroupTissuesTranscriptional RegulationX-Ray CrystallographyXenobioticsaryl hydrocarbon receptor ligandautism spectrum disorderbHLH-PAS factor HLFbasehigh throughput screeninghuman tissuehypoxia inducible factor 1neuropsychiatric disorderprogramsprotein functionpublic health relevanceresponsesensorsmall moleculetooltranscription factortumor initiation
项目摘要
DESCRIPTION (provided by applicant): The basic Helix-Loop-Helix-Per/Arnt/Sim (bHLH-PAS) family is a major group of transcription factors in mammals. Functional heterodimers in this family form via a tissue-restricted subunit, such as the hypoxia- inducible factors (HIFs), neuronal PAS (NPAS) proteins, or aryl hydrocarbon receptor (AHR), and a common dimerization subunit, such as aryl hydrocarbon receptor nuclear translocator (ARNT). Family members contain tandem PAS domains and a DNA-binding domain. PAS domains have the potential to act as molecular sensors and transmit signals to regulate the activities of these transcription factors. The HIF subgroup within the family regulates genetic programs critical in human tumor initiation, progression, invasion and metastasis. Several NPAS proteins have been genetically linked to human neuropsychiatric disorders. AHR recognizes and responds to a spectrum of xenobiotic molecules and drives gene programs necessary for detoxification. Our current knowledge about the architectures of these heterodimers, their ligand-binding pockets, and ligand- responsive activities is limited. Therefore, we have begun to conduct detailed structural investigations into several bHLH-PAS heterodimers in complexes that include bound DNA and small-molecule ligands. Our proposed structural characterizations will be complemented with chemical biology and cell-based studies to deepen our understanding of structure-function relationships in this family. The overall goals of this proposal include characterizing distinct bHLH-PAS heterodimers by X-ray crystallography, interrogating the location and composition of their ligand-binding pockets, identifying new tool compounds, and examining how ligands and disease-linked mutations manifest their actions through protein architectures.
描述(由适用提供):基本的Helix-Loop-helix-per/arnt/sim(BHLH-PAS)家族是哺乳动物的主要转录因子。通过组织限制的亚基(例如低氧诱导因子(HIF),神经元PAS(NPAS)蛋白或芳基烃受体(AHR)和常见的二聚化亚基,例如芳基氢核核核核转运器(ART))。家庭成员包含串联PAS域和DNA结合域。 PAS结构域有可能充当分子传感器并发射信号以调节这些转录因子的活性。家族中的HIF亚组调节对人类肿瘤起始,进展,入侵和转移至关重要的遗传程序。几种NPA蛋白已与人类神经精神疾病有关。 AHR识别并响应了异种生物分子的光谱,并驱动了排毒所需的基因程序。我们目前对这些异二聚体,配体结合口袋和配体反应性活动的架构的了解是有限的。因此,我们已经开始在包括结合DNA和小分子配体的复合物中对几个BHLH-PAS异二聚体进行详细的结构投资。我们提出的结构特征将通过化学生物学和基于细胞的研究完成,以加深我们对这个家庭结构功能关系的理解。该提案的总体目标包括通过X射线晶体学表征不同的BHLH-PAS异二聚体,询问其配体结合口袋的位置和组成,识别新的工具化合物,并检查如何通过蛋白质建筑表现出配体和疾病链接的突变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FRAYDOON RASTINEJAD其他文献
FRAYDOON RASTINEJAD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FRAYDOON RASTINEJAD', 18)}}的其他基金
Identification of Hypoxia-Inducible Factor-2alpha Activators for Chronic Kidney Disease Anemia
慢性肾病贫血缺氧诱导因子 2α 激活剂的鉴定
- 批准号:
9906953 - 财政年份:2018
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Hypoxia-Inducible Factor-2alpha Activators for Chronic Kidney Disease Anemia
慢性肾病贫血缺氧诱导因子 2α 激活剂的鉴定
- 批准号:
9577222 - 财政年份:2018
- 资助金额:
$ 38.51万 - 项目类别:
Structural Biology of Multi-Domain Nuclear Receptor Complexes
多域核受体复合物的结构生物学
- 批准号:
9159659 - 财政年份:2017
- 资助金额:
$ 38.51万 - 项目类别:
Molecular Characterization of Mammalian bHLH-PAS Transcription Factors
哺乳动物 bHLH-PAS 转录因子的分子表征
- 批准号:
9324331 - 财政年份:2016
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Rev-Erb alpha/beta nuclear receptor modulators
Rev-Erb α/β 核受体调节剂的鉴定
- 批准号:
8671893 - 财政年份:2014
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Allsoteric Ligands for Hepatic Nuclear Factor 4-alpha
肝核因子 4-α 变构配体的鉴定
- 批准号:
8421932 - 财政年份:2012
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Allsoteric Ligands for Hepatic Nuclear Factor 4-alpha
肝核因子 4-α 变构配体的鉴定
- 批准号:
8775220 - 财政年份:2012
- 资助金额:
$ 38.51万 - 项目类别:
Structural Characterization of Metabolic Gene Regulators
代谢基因调控因子的结构表征
- 批准号:
8728842 - 财政年份:2011
- 资助金额:
$ 38.51万 - 项目类别:
Structural Characterization of Metabolic Gene Regulators
代谢基因调控因子的结构表征
- 批准号:
8339923 - 财政年份:2011
- 资助金额:
$ 38.51万 - 项目类别:
Structural Characterization of Metabolic Gene Regulators
代谢基因调控因子的结构表征
- 批准号:
8538964 - 财政年份:2011
- 资助金额:
$ 38.51万 - 项目类别:
相似国自然基金
内源激动剂ArA靶向TMEM175蛋白缓解帕金森病症的分子机制研究
- 批准号:32300565
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Adrb2激动剂在改善呼吸机相关性膈肌功能障碍中的作用与机制研究
- 批准号:82372196
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
- 批准号:82303819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于OSMAC-GNPS分析策略的蚂蚱内生真菌Aspergillus sp.中新颖泛PPAR激动剂的发现及治疗NASH研究
- 批准号:82304340
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
探究FSP1激动剂在治疗肾缺血再灌注损伤中的分子机理与应用
- 批准号:82304600
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Novel Mechanism of aryl hydrocarbon receptor-mediated differential gene regulation
芳烃受体介导的差异基因调控新机制
- 批准号:
9976506 - 财政年份:2019
- 资助金额:
$ 38.51万 - 项目类别:
Novel Mechanism of aryl hydrocarbon receptor-mediated differential gene regulation
芳烃受体介导的差异基因调控新机制
- 批准号:
9802904 - 财政年份:2019
- 资助金额:
$ 38.51万 - 项目类别:
Novel mechanism of aryl hydrocarbon receptor - mediated differential gene regulation
芳烃受体介导差异基因调控的新机制
- 批准号:
10612044 - 财政年份:2019
- 资助金额:
$ 38.51万 - 项目类别:
Mechanistic Insights into Aryl Hydrocarbon Receptor Regulation of Fibroblast Growth Factor 21 and its Influence on Systemic Energy Metabolism
成纤维细胞生长因子 21 芳基烃受体调节的机制及其对全身能量代谢的影响
- 批准号:
9760975 - 财政年份:2019
- 资助金额:
$ 38.51万 - 项目类别:
Novel mechanism of aryl hydrocarbon receptor - mediated differential gene regulation
芳烃受体介导差异基因调控的新机制
- 批准号:
10399477 - 财政年份:2019
- 资助金额:
$ 38.51万 - 项目类别: